ACC 24 Late-Breaker Discussion: The ARISE-HF Trial

Published: 08 Apr 2024

  • Views:

    Views Icon 355
  • Likes:

    Heart Icon 3
Average (ratings)
No ratings
Your rating

ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).

This phase 3 multicenter, randomized, placebo-controlled, 2-part study evaluated the safety and efficacy of an aldose reductase inhibitor (ARI), AT-001, in patients with diabetic cardiomyopathy

Findings presented first at ACC.24 showed that AT-001 was safe and well-tolerated but did not result in a statistically significant difference in peak VO2 in patients with diabetic cardiomyopathy and reduced exercise capacity, however, it should be noted that the participants of ARISE-HF had well controlled type II diabetes mellitus (A1c=6.98%) which might not reflect outcomes in individuals with diabetic cardiomyopathy more generally.

Recorded remotely from Boston and Hamilton, 2024.

Support: This is an independent content produced by Radcliffe Cardiology.

For more content from ACC.24 head to the Late-breaking Science Video Collection.


Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Mirjam Boros

Video Specialists: Tom Green, Mike Knight


You must be to comment. If you are not registered, you can register here.